How should a dry cough caused by an ACE inhibitor be managed?

Management of ACE Inhibitor-Induced Cough

Discontinue the ACE inhibitor immediately and switch to an angiotensin receptor blocker (ARB)—this is the only uniformly effective intervention and the Grade A recommendation from the American College of Chest Physicians. 1, 2

Confirming the Diagnosis

• Stop the ACE inhibitor regardless of when the cough started relative to medication initiation—temporal relationship does not rule out ACE inhibitor as the cause. 1
• Expect cough resolution within 1-4 weeks after discontinuation in most patients, though up to 3 months may be required in a subset of individuals. 1, 2
• The diagnosis is confirmed only when cough resolves after stopping the medication—resolution is the diagnostic criterion. 1, 3

Primary Management: Switch to an ARB

• ARBs are first-line alternatives because they do not inhibit ACE, therefore do not cause bradykinin accumulation, and have cough rates similar to placebo (2-3% vs 7.9% with ACE inhibitors). 2, 3
• Start with losartan 25 mg once daily as the most studied ARB for ACE inhibitor-induced cough, titrating to 50 mg once daily if needed for blood pressure control. 3
• Alternative ARBs include:
  • Candesartan 4-8 mg once daily (up to 32 mg daily) 3
  • Valsartan 20-40 mg twice daily (up to 160 mg twice daily) 3
• All ARBs have equivalent cough profiles—choice should be based on comorbidities, dosing convenience, and cost rather than cough risk. 3
• Monitor blood pressure, renal function, and potassium within 1-2 weeks after switching to an ARB. 3

Alternative Pharmacologic Cough Suppression (If ACE Inhibitor Must Be Continued)

If there are compelling indications to continue ACE inhibitor therapy despite cough, the following agents have demonstrated efficacy in randomized controlled trials:

• Calcium channel blockers: Amlodipine 5 mg once daily (61% response rate) or nifedipine 30 mg daily (51% response rate) 1, 2, 3
• Inhaled sodium cromoglycate: 20 mg four times daily showed reduction in 90% of patients 1, 2
• Ferrous sulfate: 256 mg once daily for 28 days resulted in 45% reduction in cough scores 1, 4
• Intermediate-dose aspirin: 500 mg daily (not low-dose 100 mg) suppressed cough in 93% of patients, though use caution in elderly 1, 5
• NSAIDs: Indomethacin 50 mg twice daily or sulindac—use with caution due to cardiovascular and renal risks 1, 2
• Theophylline has shown efficacy but requires monitoring for toxicity 1, 2

Important Clinical Considerations

• Do not switch to another ACE inhibitor—cough is a class effect and will recur with any agent in this class. 3, 6
• Higher risk populations include women, nonsmokers, and persons of Chinese origin (up to 50% incidence in the latter). 1, 2, 3
• Rare angioedema risk with ARBs exists in patients who previously experienced ACE inhibitor-related angioedema—monitor closely during initial treatment. 3
• Consider rechallenge in select cases: Approximately 30% of patients with confirmed ACE inhibitor-induced cough who were challenged and dechallenged twice did not develop cough after a third trial, suggesting rechallenge may be attempted if there are compelling indications. 1, 7

Mechanism (For Understanding)

• Bradykinin and substance P accumulation in the airways occurs when ACE is inhibited, as ACE normally degrades these compounds. 2, 7
• Prostaglandin production is stimulated by elevated bradykinin levels, further contributing to cough reflex sensitization. 1, 7
• The cough is not dose-dependent—reducing the ACE inhibitor dose will not eliminate the cough. 7

Monitoring After Switching

• Cough should resolve within 1-4 weeks after switching to an ARB, confirming the diagnosis. 3
• If cough persists beyond 3 months, investigate alternative causes including pulmonary congestion, respiratory infections, lung disease, and post-nasal drip. 2, 3
• Ensure adequate blood pressure control after switching—combination therapy may be necessary if monotherapy is insufficient. 2